Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Acetamide

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44258   clinical trials with a EudraCT protocol, of which   7344   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    49 result(s) found for: Acetamide. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2006-001652-12 Sponsor Protocol Number: ICA 17043-12 Start Date*: Information not available in EudraCT
    Sponsor Name:Icagen Inc.
    Full Title: An Open-Label Extension Study Evaluating the Long-Term Safety of ICA 17043 with or without Hydroxyurea Therapy in Subjects with Sickle Cell Disease
    Medical condition: Sickle Cell Disease
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Ongoing) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-002114-11 Sponsor Protocol Number: SER-LEV-2004-01 Start Date*: 2005-05-09
    Sponsor Name:Infociencia Clinical Research
    Full Title: A double blind, randomized, placebo-controlled, cross-over study to evaluate the effects of Levetiracetam on membrane excitability properties of afferent myelinated and unmyelinated fibers and chan...
    Medical condition: Neuropathic pain due to a traumatic nerve lesion
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-000427-26 Sponsor Protocol Number: Start Date*: 2009-06-25
    Sponsor Name:Queen Victoria Hospital NHS Foundation Trust
    Full Title: A Comparison of Pre−Medication with Oral Paracetamol versus Intravenous Paracetamol Given at Time of Induction for Postoperative Analgesia Following Wisdom Tooth Extraction
    Medical condition: Pain post wisdom tooth extraction
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-001564-22 Sponsor Protocol Number: M5161/-02 Start Date*: 2006-10-17
    Sponsor Name:Maruho Co, Ltd. Kyoto R&D Center
    Full Title: A Phase IIa Multiple-Centre Randomized, Double-Blind, Placebo- Controlled, Parallel Group Study To Investigate The Efficacy Of M5161 In Relieving Pruritus Associated With Atopic Dermatitis.
    Medical condition:
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-004617-42 Sponsor Protocol Number: ICA-17043-10 Start Date*: 2005-06-22
    Sponsor Name:Icagen Inc
    Full Title: A Phase III, Multicenter, 52-Week, Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Efficacy and Safety of ICA-17043 with or without Hydroxyurea Therapy in Patients with Sickle Ce...
    Medical condition: Sickle Cell Disease
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-003171-21 Sponsor Protocol Number: LEV-2005 Start Date*: 2005-11-02
    Sponsor Name:Danish Pain Research Center
    Full Title: Effect of levetiracetam in spinal cord injury pain: a randomized, double-blind, placebo-controlled crossover study
    Medical condition: Neuropathic pain following spinal cord injury
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2008-001098-13 Sponsor Protocol Number: NA Start Date*: 2008-04-30
    Sponsor Name:UZ Leuven
    Full Title: Simultaneous administration of lorazepam and levetiracetam in non-convulsive status epilepticus, followed by IV valproate: a prospective, randomized, placebo-controled, double-blind pilot trial.
    Medical condition: Non-convulsive status epilepticus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-003701-25 Sponsor Protocol Number: 7035-CL-0014 Start Date*: 2013-12-09
    Sponsor Name:Tacurion Pharma Inc
    Full Title: A Phase II, Multicenter,Randomization, Double-Blind, Parallel Group, Placebo-Controlled, Forced Titration Proof of Concept Study to Assess Efficacy, Safety, Tolerability and the Therapeutic Ratio ...
    Medical condition: Nocturia associated with nocturnal polyuria
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004857 10064016 Nocturnal polyuria LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: BE (Completed) PL (Completed) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-006088-23 Sponsor Protocol Number: MEK116513 Start Date*: 2012-06-20
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase III, randomised, open-label study comparing the combination of the BRAF inhibitor, dabrafenib and the MEK inhibitor, trametinib to the BRAF inhibitor vemurafenib in subjects with unresectab...
    Medical condition: Metastatic melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed) BE (Completed) AT (Completed) NO (Completed) IE (Completed) CZ (Completed) ES (Completed) NL (Completed) HU (Completed) FI (Completed) IT (Completed) PL (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2004-001339-41 Sponsor Protocol Number: N01175 Start Date*: 2004-12-22
    Sponsor Name:UCB S.A. Pharma Sector
    Full Title: A therapeutic confirmatory, open-label, multi-center, randomized 2 parallel groups, community-based trial studying the efficacy and safety of levetiracetam (1000 to 3000 mg/day oral tablets 250-50...
    Medical condition: Monotherapy in subjects with newly diagnosed epilepsy
    Disease: Version SOC Term Classification Code Term Level
    7.0 10015037 LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) FI (Completed) SE (Completed) SK (Completed) IE (Completed) CZ (Completed) GB (Completed) DE (Completed) BE (Completed) ES (Completed) IT (Completed) HU (Completed) PT (Not Authorised) DK (Completed)
    Trial results: View results
    EudraCT Number: 2004-001997-13 Sponsor Protocol Number: N167 Start Date*: 2004-11-22
    Sponsor Name:UCB S.A. Pharma Sector
    Full Title: An open-label, multicenter, follow-up study to evaluate the safety and efficacy of levetiracetam (LEV) (oral tablets of 166, 250 or 500 mg b.i.d.), at individualized doses up to a maximum of 4000 m...
    Medical condition: Neurology, epilepsy, primary generalized seizures
    Disease: Version SOC Term Classification Code Term Level
    10018079 LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2016-001900-47 Sponsor Protocol Number: 57719 Start Date*: 2017-06-08
    Sponsor Name:Maastricht University Medical Centre +
    Full Title: The effect of lidocaine infusion on ad libitum food intake and satiety in healthy volunteers
    Medical condition: food intake and satiety
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-001302-27 Sponsor Protocol Number: N01142 Start Date*: 2005-06-10
    Sponsor Name:UCB S.A. Pharma Sector
    Full Title: An 8-week exploratory, double-blind, placebo controlled, randomized trial : Evaluation of the efficacy and safety of levetiracetam up to 3000 mg/day (250-500 mg oral tablets in b.i.d. administratio...
    Medical condition: Tardive dyskinesia usually occurs after prolonged exposure to antipsychotics and is characterized by abnormal choreiform, athetoic, choreathetoic or rhythmic involuntary movements. The localizatio...
    Disease: Version SOC Term Classification Code Term Level
    7.1 10013928 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-011525-13 Sponsor Protocol Number: V001 Start Date*: 2009-08-28
    Sponsor Name:Vernalis (R&D) Limited
    Full Title: Phase II Open-label Pilot Study of V3381, a Novel N-Methyl-D-Aspartate Receptor Antagonist, in Chronic Cough Patients attending a Specialist Clinic
    Medical condition: Treatment resistant and Idiopathic Chronic Cough
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066656 Chronic cough LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005827-35 Sponsor Protocol Number: RC31/20/0441 Start Date*: 2021-03-25
    Sponsor Name:University Hospital of Toulouse
    Full Title: SARS-CoV-2 neurotropism, micRoglial ActivatioN and cytokine dySregulaTiOn in COVID-19 patients with delirium
    Medical condition: delirium
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-004577-12 Sponsor Protocol Number: BRF116613 Start Date*: 2015-03-23
    Sponsor Name:GlaxoSmithKline, S.A.
    Full Title: Phase II biomarker study evaluating the upfront combination of BRAF inhibitor dabrafenib with MEK inhibitor trametinib versus the combination after eight weeks of monotherapy with dabrafenib or tra...
    Medical condition: patients with metastatic and unresectable stage III or IV melanoma harbouring an activating BRAF mutation
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10027156 Skin melanomas (excl ocular) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-004053-26 Sponsor Protocol Number: SEEG 0001 Start Date*: 2005-04-14
    Sponsor Name:Birthe Pedersen
    Full Title: An explorative use open-label, multi-center, randomized trial studying the safety and efficacy of levetiracetam (500 mg/day to 3000 mg/day) and valproate (600 mg/day to 3000 mg/day) as monotherapy ...
    Medical condition: Newly diagnosed epilepsy patients are over 65 years. In this age group more cases are symptomatic and it is apparently another disorder than epilepsy in adults. Epilepsy in the elderly is easier to...
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-005711-10 Sponsor Protocol Number: OX22-006 Start Date*: 2007-02-26
    Sponsor Name:Orexo AB
    Full Title: A double-blind, randomised, two-period crossover study to evaluate the hypnotic effects and safety of sublingual zolpidem for the treatment of insomnia.
    Medical condition: Primary insomnia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10036701 Primary insomnia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2022-003415-29 Sponsor Protocol Number: 2.0 Start Date*: 2023-04-03
    Sponsor Name:Leiden University Medical Centre
    Full Title: The effect of antenatal acetaminophen administration on breathing effort of premature infants at birth: a pilot study
    Medical condition: Pregnant women expected to deliver between 24 and 30 weeks' gestation
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004848 10033762 Paracetamol LLT
    Population Age: In utero, Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-005006-62 Sponsor Protocol Number: ASZ-001 Start Date*: 2019-12-10
    Sponsor Name:Albert Schweitzer hospital
    Full Title: Pharmacokinetics of Paracetamol before and after Roux-en-Y gastric bypass
    Medical condition: Roux-en-Y gastric bypass
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004848 10033762 Paracetamol LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA